Venetoclax-Obinutuzumab Boosts MRD Clearance in CLL Edited by Gargi Mukherjee July 06, 2026 Blood. 2026;147(24):2895-2904. doi:10.1182/blood.2025030630

https://www.medscape.com/viewarticle/venetoclax-obinutuzumab-boosts-mrd-clearance-cll-2026a1000mqf?src= In fit patients with untreated chronic lymphocytic leukemia (CLL), first-line treatment with fixed-duration venetoclax-obinutuzumab was associated with higher undetectable minimal residual disease (MRD) rates than fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in the phase 3 CRISTALLO trial.